In Depth 31 Jan 2017 Biologicals on the Brain: Biotech in Neurodegenerative Disease Brain diseases are hard to treat, but biotechs are harnessing a variety of techniques, including immunotherapy and gene therapy, to target neurodegenerative disorders. When Eli Lilly announced that solanezumab, a long anticipated Alzheimer’s antibody, failed in their third attempt at a late stage trial last year, it crushed patients’ hopes and raised doubts about whether […] January 31, 2017 - 7 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2017 Novo Nordisk will open a €135M Diabetes R&D Center at Oxford University A new research center funded by Novo Nordisk will foster collaborations between its staff and researchers from the University of Oxford. Novo Nordisk and the University of Oxford have announced a collaboration focused on type 2 diabetes research. As part of the effort, the Danish pharma will invest €135M (£115M) over a 10-year period to […] January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2017 The FDA gives Fast Track Priority to uniQure’s Hemophilia B Gene Therapy UniQure has received Breakthrough Therapy Designation from the FDA, granting fast track to its gene therapy for hemophilia B. UniQure is one of the companies leading the development of gene therapy for hemophilia. Now, the FDA has granted Breakthrough Therapy Designation to its candidate AMT-060 for hemophilia B. This is awarded to selected therapies that have […] January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2017 ‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small size and high solubility. The company has now received a milestone payment from Danish pharma Lundbeck for the development of the technology as a delivery […] January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jan 2017 The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge Cambridge’s image is tied to its Hogwarts-like University and Nobel-hoarding academia, but there’s also an exciting entrepreneurial scene at the cutting edge of technology. We took a look at how big biotech is in the Silicon Fen. Cambridge’s Biotech cluster has an exemplary hive of talent, infrastructure, and capital – enough to create the same vibe […] January 30, 2017 - 8 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
More News! 28 Jan 2017 Microbes Control the Massive Turbine Hall at London’s Tate Modern Philippe Parreno’s Anywhen, occupying the vast hall at Tate Modern, evolves over time in response to the control of tiny living beings. When you enter Tate Modern‘s vast Turbine Hall, you might see lights turning off and on and hear noises coming and going. Without an apparent pattern, sounds and light evolve while families take […] January 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 27 Jan 2017 Needle-free Treatments for Autoimmune Disorders from Switzerland It’s back to go back to the mainland. This week’s stop is in Hergiswill, a city by one of the many beautiful seas that can be found in Switzerland. There, the young biotech BioLingus is developing needle-free therapies for chronic diseases. City: Hergiswill, Switzerland Founded: 2014 Employees: 1-10 Financial data: N/A Mission: BioLingus develops non-invasive treatments for autoimmune and inflammatory […] January 27, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jan 2017 Bad News for Diabetics: Eli Lilly Abandons French Ultra-Rapid Insulin Eli Lilly has decided to terminate its partnership with Adocia for the development of BioChaperone Lispro, an ultra-rapid insulin for diabetes. Despite results from 6 clinical studies indicating that Adocia’s ultra-rapid insulin performs better than Eli Lilly’s Humalog, the big American pharma has decided to terminate its collaboration with the French biotech. As part of this […] January 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jan 2017 Researchers are One Step Closer to Understanding Artificial Silk Silk is a material in high demand, and so is a method to produce it artificially. A Swedish-German team of researchers is studying how to make silk with milk whey protein. Besides making way for a potentially cheaper process, artificial silk could have important medical applications. Researchers from the Royal Institute of Technology (KTH) in Stockholm and […] January 27, 2017 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2017 Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B Actelion will be acquired by J&J for a whopping €27.9B, and its early R&D pipeline will be spun out into a new Switzerland-based outfit. The wait is over folks: Actelion, the largest biotech in Europe and one of the only 9 to make it to the billion-euro club in 2016, has just announced its acquisition by Johnson & Johnson for a […] January 26, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2017 Novartis Relies on Biotech to keep up its Solid Financial Performance Novartis has announced excellent results for 2016. Could its strong focus on biotech be the key to the big pharma’s success? Novartis just released its 2016 financial report, boasting €45.2B ($48.5B) in net sales and its therapeutic antibody for psoriasis, Cosentyx (secukinumab), becoming a blockbuster. The Swiss pharma is suffering competition from generics, but it expects […] January 25, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2017 Update: From Lupus to a Vaccine for Diabetes Type I? Dates Announced Update (25/01/2016): NeoVacs has announced plans to obtain preclinical proof of concept in 2017 for its type 1 diabetes program and to initiate clinical development in the first half of 2018 with the recommendation of its Scientific Advisory Board. Published on 13/10/2016 Neovacs has announced a research collaboration that could lead to the development of […] January 25, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email